SPOTLIGHT: Investors cheer Progen data

Australia's Progen Industries saw its share surge after researchers announced that its experimental liver cancer drug demonstrated statistically significant results. Patients taking PI-88 following the removal of a cancerous tumor went an average of 30 weeks before it grew back, compared to 17 weeks for patients who weren't taking the drug. Release | Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.